Saxenda 6mg/ml Prefilled Pen | Weight Loss Treatment

Saxenda is a medicine used in the treatment of obesity. The treatment works by preventing the body from absorbing fats in your diet.


Treatments start from £299.99


Prescription Only Medicine Saxenda is a Prescription Only Medicine. Please click on the link below to select your treatment and start your online GP consultation.

Availability: In stock

£299.99

* Required Fields

Categories

Description
Details

Therapeutic Indications:

Saxenda® (liraglutide injection 3 mg) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of:

• ≥ 30 kg/m² (obesity), or

• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

Treatment with Saxenda® should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.

Saxenda® should not be used in combination with another GLP-1 receptor agonist.

In adult patients with type 2 diabetes, when initiating Saxenda®, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycaemia.

Dosing and Shelf Life:

The starting dose is 0.6 mg once daily. The dose should be increased to 3.0 mg once daily in increments of 0.6 mg with at least one week intervals to improve gastro-intestinal tolerability. If escalation to the next dose step is not tolerated for two consecutive weeks, consider discontinuing treatment. The maintenance dose is 3.0 mg. Daily doses higher than 3.0 mg are not recommended.

Each pen contains 3 ml clear, colourless solution and is able to deliver doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg.   Store in refrigerator (2°C-8°C).  Do not freeze.  Store away from freezer compartment.  After first use, store below 30°C.  Shelf life 30 months.  After first use, one month.

Summary of the safety profile:

Overall, gastrointestinal reactions were the most frequently reported adverse reactions during treatment with Saxenda®.

Most episodes of gastrointestinal events were mild to moderate, transient and the majority did not lead to discontinuation of therapy. The reactions usually occurred during the first weeks of treatment and diminished within a few days or weeks on continued treatment. Patients ≥65 years of age may experience more gastrointestinal effects when treated with Saxenda®. Patients with mild or moderate renal impairment (creatinine clearance ≥30 mL/min) may experience more gastrointestinal effects when treated with Saxenda®.

Please refer to the full Summary of Product Characteristics on the eMC website (medicines.org.uk) for a complete list of adverse reactions, or call the Novo Nordisk Customer Care Line on 0845 600 5505 for further information.

 

 Manufacturer: Novo Nordisk
 Dosage Strength: 0.6mg
 Active Ingredient: Liraglutide
 How to Take Saxenda: Begin with 0.6mg daily 
 

 For full details on Saxenda® (liraglutide injection 6 mg) please click on the patient leaflet below:

 Saxenda 6mg Patient Information Leaflet

Product Information

Details

How to use Saxenda

Please refer to this link to watch a video on how to use the Saxenda pen.

How to use the Saxenda pen from NationWide Pharmacies on Vimeo.

Source: https://www.saxenda.com

We also strongly recommend any patients who use Saxenda take a look at WeightJourney™ - a complimentary support program to help you work toward your weight-management goals - This program is only available for individuals who have been prescribed Saxenda.

How does Saxenda work?

Liraglutide is an acylated human Glucagon-Like Peptide-1 (GLP-1) analogue with 97% amino acid sequence homology to endogenous human GLP-1. Liraglutide binds to and activates the GLP-1receptor (GLP-1R). GLP-1 is a physiological regulator of appetite and food intake, but the exact mechanism of action is not entirely clear. In animal studies, peripheral administration of liraglutide led to an uptake in specific brain regions involved in regulation of appetite, where liraglutide, via specific activation of the GLP-1R, increased key satiety and decreased key hunger signals, thereby leading to lower body weight.

Pharmacodynamic effects

Liraglutide lowers body weight in humans mainly through loss of fat mass with relative reductions in visceral fat being greater than for subcutaneous fat loss. Liraglutide regulates appetite by increasing feelings of fullness and satiety while lowering feelings of hunger and prospective food consumption, thereby leading to reduced food intake. Liraglutide does not increase energy expenditure compared to placebo.

Adverse Events Reporting

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions to the MHRA through the yellow card scheme online at www.mhra.gov.uk/yellowcard

Adverse events and medications errors should also be reported to the Novo Nordisk Customer Care Line on 0845 600 5055.  Charges may vary, please check with your service provider.  Calls may be monitored for training purposes.  Office hours are 8:00am – 8:00pm weekdays and Bank Holidays.

Who can use Saxenda?

Where weight management has not succeeded in using a calorie controlled diet and an increased level of physical activity, Saxenda can be used as an adjunct to therapy.

Indicated for those individuals with a Body Mass Index (BMI) of;

>30kg/m2 (obese)

>27kg/m2 but <30kg/m2 (overweight) – must be accompanied by at least one other risk factor such as unregulated blood glucose levels (pre-diabetes, Type II Diabetes), high blood pressure (hypertension), dyslipidaemia and obstructive sleep apnoea.

 BMI = Weight (kg) / (Height (m) x Height (m))

Patients can expect to lose a minimum of 5% of their initial body weight after completing 12 weeks of treatment at 3.0mg Liraglutide daily.  If this has not occurred then treatment should be discontinued at this stage.

What is the Dosage of Liraglutide to be used?

The initial dose is 0.6mg Liraglutide daily and should be increased at intervals of 0.6mg as follows –
  • Week 1 – 0.6mg daily
  • Week 2 – 1.2mg daily
  • Week 3 – 1.8mg daily
  • Week 4 – 2.4mg daily
  • Week 5 onwards – maintenance dose of 3.0mg daily

DOSAGE IS TAKEN AS A ONCE DAILY INJECTION

Dosage is increased slowly to minimise any unwanted effects on the gastro-intestinal tract.  If an increase to a higher dose cannot be tolerated following 2 continuous weeks, then consider discontinuing drug treatment.  The maximum recommended daily dosage of Liraglutide is 3.0mg.

Always use Saxenda exactly how your prescriber has told you.  Check with your doctor, pharmacist or nurse if you are unsure.

Saxenda is a subcutaneous injection and should, therefore, be injected under the skin.  The best sites for injection are the front of the waist (abdomen), the front of your thigh or the upper arm.  Take extra care not to inject into a vein or muscle.

Detailed instructions on injection techniques are included within the patient information leaflet which is provided with the product.  Patients are advised to follow these instructions carefully.

For a detailed guide, including a video demonstration, on how to use Saxenda please visit www.weightjourney.co.uk 

This site has been developed by Novo Nordisk (the manufacturer's of Saxenda) and contains a wealth of information.  Patients are strongly advised to complete the 4 modules contained within the site after registration as these have been designed to complement therapy and answer most questions patients may have in relation to their weight loss journey.

 (Last 6 digits of Bar Code - 530006 - required for registration)

Special Considerations and Patients Who Cannot Use Saxenda

Elderly (>65 years old) – no dose adjustment is required for this age group however results can be limited in those over the age of 75

Renal Impairment – No dose adjustment is needed for those with mild to moderate renal impairment (CrCl >30ml/min).  For severe or end stage renal impairment (CrCl <30ml/min) Saxenda is not recommended.

Hepatic Impairment – Although no dose adjustment is needed, Saxenda should be used with caution in those with mild to moderate hepatic impairment.  Use of Saxenda is not recommended in those severe hepatic impairment.

There is no clinical data for use in children and therefore is not recommended for administration to a paediatric population.

Diabetics – concurrent use in diabetics already taking medication should be avoided due to the risk of hypoglycaemia.  Patients taking insulin or drugs which regulate insulin may need their doses adjusted if Liraglutide is administered at the same time. 

Treatment with Saxenda should be avoided if there are any known sensitivity reactions to Liraglutide or any of the excipients. 

There have been little or no studies done in patients who are suffering from heart failure.  Due to this lack of data, it is therefore not recommended for use in this group of patients.

 Saxenda is not recommended if you suffer from severe gastro-intestinal issues such as inflammatory bowel disease or gastroparesis.

 A doctor should be consulted before starting treatment if you suffer from any form of a thyroid disorder.

What are the Side Effects Associated with Saxenda?

As with all medication, Saxenda can be associated with unwanted side effects.  Although generally mild in nature some of these can be more severe which can result in the treatment being discontinued. 

When treatments is initially started, some individuals may result in a loss of bodily fluids.  This can be a result of gastro disturbances such as vomiting or diarrhoea.  It is important to ensure you drink plenty of fluids and keep yourself well hydrated whilst taking Saxenda.  Most mild side effects will settle once your body gets accustomed to the new medication.  However, as always, if any side effects persists then treatment should be discontinued and your doctor should be consulted.

 Side effects can include (but are not limited to) –

 VERY COMMON

  • Nausea & vomiting (settles after your body adjusts to treatment)
  • Diarrhoea (settles after your body adjusts to treatment)

  COMMON

  • Low blood sugar (hypoglycaemia) – signs of this may include tremor, feeling weak & hungry, sweating, cold or cool skin, feeling sleepy, difficulty in concentrating, confusion, headache, anxiety, feeling nervous, faster heart rate.
  • Nausea
  • Headache
  • Gastro-intestinal disturbances – Indigestion, reflux (GORD), inflammation, painful, swollen abdomen, excess wind, constipation.
  • Common cold symptoms – Tiredness (fatigue), Pyrexia (fever), dizziness.
  • Loss of appetite
  • Local reactions around the injection site – rash, itch, pain, bruising, swelling

 UNCOMMON

  • Thyroid reactions such as goitres, nodules.
  • Pancreatitis

 VERY RARE

  • Angioedema

List compiled from data taken from www.medicines.org.uk – Please visit their website for full and comprehensive list. 

FAQs

Details

What is Saxenda®? 

Saxenda® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of1: ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).

How does Saxenda® work?

Saxenda® lowers body weight through decreased calorie intake. Saxenda® does not increase 24-hour energy expenditure.1

Saxenda® is an acylated human GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1 (7-37).1

GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. In animal studies, peripheral administration of liraglutide resulted in the presence of liraglutide in specific brain regions regulating appetite, including the hypothalamus. Although liraglutide activated neurons in brain regions known to regulate appetite, specific brain regions mediating the effects of liraglutide on appetite were not identified in rats.

How is Saxenda® supplied?

Saxenda® is supplied in a prefilled pen. Each prescription is a box of 3 or 5 prefilled multidose pens, each containing 18 mg/3 mL of liraglutide that can deliver the 0.6-, 1.2-, 1.8-, 2.4-, and 3-mg doses.

How is Saxenda® administered? 

Saxenda® is subcutaneously injected in the abdomen, thigh, or upper arm using a prefilled, multidose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Saxenda® can be taken once daily at any time, independent of meals.

Needles are sold separately and may require a prescription in some states.

Refer to the Instructions for Use for full details on administration.

What are the most common side effects patients have experienced?

The most common adverse reactions reported in under 5% of patients were: nausea, hypoglycemia, diarrhoea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, and increased lipase.

How is Saxenda® stored?

Store new, unused Saxenda® pens in the refrigerator at 36°F to 46°F (2°C to 8°C). After first use, store pens at 59°F to 86°F (15°C to 30°C) or in a refrigerator at 36°F to 46°F (2°C to 8°C). Pens should be thrown away after 30 days, even if they still have Saxenda® left in them. Don’t freeze Saxenda®. Saxenda® that has been frozen should not be used. Each Saxenda® pen is for use by a single patient. Never share a Saxenda® pen between patients, even if the needle has been changed.

Our Service

Details

Prescription Orders:

NationWide Pharmacies Online Doctor service offers a fast and convenient way to order your prescription medication.

Simply follow the steps below:

1. Create your account

2. Select your medical condition

3. Complete the diagnostic consultation form

4. Select your treatment

5. Complete medical questionnaire

6. Complete checkout process and submit your order.

Our doctor will assess your questionnaire within 24 hours. Once your prescription has been approved it will be despatched from our pharmacy.

Delivery:

All orders are dispatched by Royal Mail 1st Class signed for delivery. The vast majority of orders are delivered next day however you should allow for up to 48 hours for delivery. In the case of high value orders we will from time to time use tracked courier services.

Next Day Delivery:

Guaranteed next working day delivery is subject to a delivery charge of £7.50. Orders are despatched by Royal Mail Special Delivery Next Day. Next Day delivery orders need to be placed before 12pm (Mon-Fri). Your order will arrive before 1pm the next working day after it has been despatched.

Saturday Delivery:

Guaranteed Saturday delivery is subject to a delivery charge of £10.50. Orders are despatched by Royal Mail Special Delivery Saturday. All Saturday delivery orders need to be placed no later than 12pm Friday’s. Your order will arrive before 1pm on the Saturday.

Reviews
Write Your Own Review
You're reviewing: Saxenda 6mg/ml Prefilled Pen | Weight Loss Treatment
How do you rate this product? *
  1 star 2 stars 3 stars 4 stars 5 stars
Rating
Product Tags
Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.

You may also be interested in the following product(s)
Xenical (Orlistat) 120mg Capsules | Weight Loss Treatment
1 Review(s)
£49.00
Xenical (Orlistat) is a medicine used in the treatment of obesity. The treatment works by preventing the body from absorbing fats in your diet. Treatments start from £49  Xenical is a Prescription Only Medicine. Please add your treatment to your cart and begin your online consultation.